The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 16, Issue SUPPL. 1, 2001, Pages

  Kennedy, J S ^a   Zagar, A ^a   Bymaster, F ^a   Nomikos, G ^a   Trzepacz, P T ^a   Gilmore, J A ^a   Rotelli, M D ^a   Breier, A ^a   Tollefson, G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's disease; Olanzapine

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; MUSCARINIC RECEPTOR; OLANZAPINE; PIRENZEPINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CHOLINERGIC NERVE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BENZODIAZEPINES; BRAIN; CHOLINERGIC FIBERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PIRENZEPINE; RECEPTORS, MUSCARINIC; RETROSPECTIVE STUDIES;

EID: 0012836543     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1166(200112)16:1+<::aid-gps570>3.0.co;2-8     Document Type: Review

References (32)

1. Arnt J, Skarsfeldt T. 1998. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacol 18: 63-101.
2. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. 1996. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol 14(2): 111-123.
3. 6 receptor in the rat brain: a study using antisense oligonucleotides. Pharmacol Exp Ther 274: 173-180.
4. 6 receptors as emerging targets for drug discovery. Annu Rev Pharmacol Toxicol 40: 319-334.
5. Bymaster FP, Falcone JF. 2000. Decreased binding affinity of olanzapine and clozapine for clonal human muscarinic receptor subtypes in intact CHO cells in physiological medium. Eur J Pharmacol 390: 245-248.
6. 1-adrenergic receptors in vitro. Schizophr Res 37(1): 107-122.
7. Bymaster F, Calligaro DO, Falcone JF, et al. 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 14: 87-96.
8. Chengappa KN, Pollock BG, Parepally H, et al. 2000. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 20(3): 311-316.
9. Davis R, Raby C, Callahan MJ, et al. 1993. Selective muscarinic antagonists: potential therapeutic agents for Alzheimer's disease. Prog Brain Res 98: 439-445.
10. Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J. 1998. The association of scrum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 6(1): 31-41.
11. 1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol 29: 256-262.
12. Kennedy JS. 2000. Olanzapine and the cholinergic system: an evolving scientific inquiry. In Olanzapine (Zyprexa®): A Novel Antipsychotic, Tran PV, Bymaster FP et al. (eds) Lippincott, Williams, and Wilkins: Philadelphia, PA; 337-341.
13. Kennedy JS, Bymaster FP, Basson BR, Gilmore JA, Tran PV. 2000a. The comparative peripheral anticholinergic-like adverse event profiles of olanzapine and risperidone. Primary Care Companion 2(4): 122-126.
14. Kennedy JS, Basson BR, Zagar AJ, et al. 2000b. The effects of olanzapine on Alzheimer's Disease assessment scale scores in patients with mild to moderate Alzheimer's disease with psychosis and behavioral disturbances. Presented at the 2000 Annual Scientific Meeting of the American Geriatrics Society and the American Federation for Aging Research; 20 May, Nashville, TN.
15. Kennedy JS, Kwentus JA, Kumar V, Schmidt D. 1998. Cholinergic system therapy for Alzheimer's disease. In Advances in the Diagnosis and Treatment of Alzheimer's Disease, Kumar V, Eisdorfer C (eds). Springer Publishing Company: New York; 298-350.
16. Lipowski ZJ. 1990. Delirium: Acute Confusional States. Oxford University Press: New York.
17. Meltzer HY, O'Laughlin IA, Dai J, Fowler WL, Ichikawa J. 1999. A typical antipsychotic drugs (APD) but not typical APD increased extracellular acetylcholine (ACh-ext) levels in rat medical prefrontal cortex (mPFC) in the absence of AChEsterase (AChE) inhibition. Soc Neurosci Abstr 25(1-2): 452. (Abstract).
18. Purdon SE, Jones BDW, Stip E, et al. 2000. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psych 57: 249-258.
19. Raedler TJ, Knable MB, Jones DW, et al. 2000. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacol 23(1):56-68.
20. Richardson JS, Miller PS, Lemay JS, et al. 1985. Mental dysfunction and the blockade of muscarinic receptors in the brains of the normal elderly. Prog Neuropsychopharmacol Biol Psychiatry 9(5-6): 651-654.
21. 6 antagonist SB-271046. Br J Pharmacol Suppl 127: 22. (Abstract)
22. Schotte A, Janssen PF, Gommeren W, et al. 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol 124(1-2):57-73.
23. Shirazi S, Rodriguez D, Nomikos GG. 2000. Effects of typical and atypical antipsychotic drugs on acetylcholine release in the hippocampus. Soc Neurosci Abstr 26: 2144. (Abstract).
24. 6 receptors. Br J Pharmacol 124: 556-562.
25. Smith CJ, Perry EK, Perry RH, Fairbairn AF, Birdsall NJM. 1987. Guanine nucleotide modulation of muscarinic cholinergic receptor binding in postmortem human brain - a preliminary study in Alzheimer's disease. Neurosci Lett 82: 227-232.
26. Street JS, Clark WS, Gannon KS, et al. 2000. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized trial. Arch Gen Psych 57(10): 968-976.
27. 6 receptor null mutant mice. 4th IUPHAR (International Union of Pharmacology) Satellite Meeting on Serotonin 1998; Rotterdam. (Abstract).
28. Thienhaus OJ, Allen A, Bennett JA, Chopra YM, Zemlan FP. 1990. Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci 240(1): 28-33.
29. Tollefson GD, Montague-Clouse J, Lancaster SP. 1991. The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci 3(3): 314-319.
30. 6 receptor polymorphism C267T in Alzheimer's disease. Neurosci Lett 276(2): 138-139.
31. Wood S, Cummings JL, Hsu MA, et al. 2000. The use of the Neuropsychiatric Inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 8(1): 75-83.
32. 2A and muscarinic receptors. Psychopharmacol 141(3): 267-278.